["crohn's disease"]
['glpg0634', 'placebo']

        Inclusion Criteria:

          -  Male or female subjects between 18 and 75 years

          -  Documented history of ileal, colonic, or ileocolonic CD

          -  CDAI score ≥ 220 to ≤ 450

          -  Evidence of active inflammation as demonstrated by endoscopic confirmation of active
             disease

          -  Subjects previously not exposed to anti-TNF treatment (TNF-naïve) or subjects
             previously exposed to anti-TNF therapy at a registered dose, that has been
             discontinued at least 8 weeks prior to Screening and deemed by the treating physician
             as a primary or secondary non-responder or intolerant (TNF-experienced)

          -  Continuation of concurrent treatment with oral steroids (≤30 mg prednisolone eq/day),
             mesalazine, olsalazine, CD-related antibiotics and probiotics at stable dose is
             allowed

          -  Previous exposure to immunomodulators is permitted, but must be discontinued

          -  Haematology and biochemistry lab parameters within predefined ranges as stated in the
             protocol

        Exclusion Criteria:

          -  Diagnosis of indeterminate colitis, ulcerative colitis (UC), or clinical findings
             suggestive of UC

          -  Stoma, gastric or ileoanal pouch, procto- or total colectomy, symptomatic stenosis or
             obstructive strictures, history of bowel perforation, (suspected) abscess; actively
             draining fistulae

          -  Subject who has had surgical bowel resections within the past 6 months, short bowel
             syndrome or is receiving tube feeding, defined formula diets, or parenteral
             alimentation

          -  Subject with positive Clostridium difficile toxin stool assay or evidence of any other
             gastrointestinal infection

          -  Subject who has received non-permitted IBD therapies within specified timeframes,
             depending on the medication, as stated in the protocol

          -  Subject with a (previous history of) dysplasia of the gastrointestinal tract

          -  Concurrent gastro-intestinal malignancy or a history of cancer elsewhere

          -  History of lymphoproliferative disease

          -  Known active infection of any kind, current therapy for chronic infection or history
             of specific infections as stated in the protocol

          -  Subject who is pregnant, lactating or not willing to maintain highly effective birth
             control methods during the course of the study and 12 weeks thereafter
      